| Title |
Current trends in drug treatment of obsessive–compulsive disorder
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, May 2010
|
| DOI | 10.2147/ndt.s3149 |
| Pubmed ID | |
| Authors |
Eric H Decloedt, Dan J Stein |
| Abstract |
This article aims to highlight current trends in the pharmacologic management of obsessive-compulsive disorder (OCD). A systematic search of the electronic database MEDLINE was conducted. The first case report of clomipramine efficacy in the management OCD more than 40 years ago gave new hope for the treatment of this debilitating disorder. Selective serotonin reuptake inhibitors (SSRIs) proved to have a similar efficacy profile compared with clomipramine but had a superior tolerability profile. While many patients with OCD respond to SSRIs or clomipramine, the treatment of those with refractory OCD remains challenging. Different augmentation agents in treatment-resistant OCD have been explored, with antipsychotic agents having the largest supporting evidence base. Nevertheless, new pharmacologic treatment options are required and are under investigation. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 2 | 3% |
| Turkey | 1 | 2% |
| Philippines | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 59 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 20% |
| Student > Master | 10 | 16% |
| Student > Bachelor | 9 | 14% |
| Student > Ph. D. Student | 9 | 14% |
| Student > Postgraduate | 4 | 6% |
| Other | 11 | 17% |
| Unknown | 8 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 33% |
| Psychology | 12 | 19% |
| Agricultural and Biological Sciences | 6 | 9% |
| Neuroscience | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Other | 6 | 9% |
| Unknown | 12 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2022.
All research outputs
#7,205,554
of 25,374,917 outputs
Outputs from Neuropsychiatric Disease and Treatment
#913
of 3,132 outputs
Outputs of similar age
#33,550
of 104,700 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#8
of 15 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 104,700 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.